Minerva Neurosciences

$2.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.00 (+0.21%) As of 2:22 PM UTC today

Why Robinhood?

You can buy or sell NERV and other stocks, options, and ETFs commission-free!

About NERV

Minerva Neurosciences, Inc Common Stock, also called Minerva Neurosciences, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease.

CEO

Rémy Henri Luthringer

Employees

Headquarters

Waltham, Massachusetts

Founded

2007

Market Cap

102.44M

Price-Earnings Ratio

56.33

Dividend Yield

—

Average Volume

294.75K

High Today

$2.45

Low Today

$2.40

Open Price

$2.44

Volume

36.01K

52 Week High

$15.22

52 Week Low

$1.81

NERV Earnings

-$0.77

-$0.27

$0.23

$0.73

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected May 3, Pre-Market